Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sigrid Klaar

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
The Lancet. Haematology|June 17, 2018
Changing views on adverse event reportingBeatriz Flores, Sigrid Klaar, Daniel J O'Connor
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancersBarbro Linderholm, Eva Karlsson, Sigrid Klaar, et al.
Carcinogenesis|November 25, 2003
Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancerThomas Lindahl, Göran Landberg, Johan Ahlgren, et al.
Acta Oncologica (Stockholm, Sweden)|May 28, 2004
Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxelPaula Poikonen, Johanna Sjöström, Sigrid Klaar, et al.
Genes, Chromosomes & Cancer|October 18, 2006
Gene expression in 16q is associated with survival and differs between Sørlie breast cancer subtypesKristian Wennmalm, Stefano Calza, Alexander Ploner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2012
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human useElias Pean, Sigrid Klaar, Eva Gil Berglund, et al.
Breast Cancer Research : BCR|July 19, 2006
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patientsStefano Calza, Per Hall, Gert Auer, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 6, 2005
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalLance D Miller, Johanna Smeds, Joshy George, et al.
Acta Oncologica (Stockholm, Sweden)|August 28, 2002
A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in SwedenJenny Andersson, Barbro Linderholm, Gudrun Greim, et al.
Breast Cancer Research : BCR|November 11, 2005
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohortsYudi Pawitan, Judith Bjöhle, Lukas Amler, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
The Lancet. Haematology|June 17, 2018
Changing views on adverse event reportingBeatriz Flores, Sigrid Klaar, Daniel J O'Connor
European Journal of Cancer (Oxford, England : 1990)|November 3, 2004
Thrombospondin-1 expression in relation to p53 status and VEGF expression in human breast cancersBarbro Linderholm, Eva Karlsson, Sigrid Klaar, et al.
Carcinogenesis|November 25, 2003
Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancerThomas Lindahl, Göran Landberg, Johan Ahlgren, et al.
Acta Oncologica (Stockholm, Sweden)|May 28, 2004
Skin toxicity as a risk factor for major infections in breast cancer patients treated with docetaxelPaula Poikonen, Johanna Sjöström, Sigrid Klaar, et al.
Genes, Chromosomes & Cancer|October 18, 2006
Gene expression in 16q is associated with survival and differs between Sørlie breast cancer subtypesKristian Wennmalm, Stefano Calza, Alexander Ploner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2012
The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human useElias Pean, Sigrid Klaar, Eva Gil Berglund, et al.
Breast Cancer Research : BCR|July 19, 2006
Intrinsic molecular signature of breast cancer in a population-based cohort of 412 patientsStefano Calza, Per Hall, Gert Auer, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 6, 2005
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survivalLance D Miller, Johanna Smeds, Joshy George, et al.
Acta Oncologica (Stockholm, Sweden)|August 28, 2002
A population-based study on the first forty-eight breast cancer patients receiving trastuzumab (Herceptin) on a named patient basis in SwedenJenny Andersson, Barbro Linderholm, Gudrun Greim, et al.
Breast Cancer Research : BCR|November 11, 2005
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohortsYudi Pawitan, Judith Bjöhle, Lukas Amler, et al.
Pageof 2